JO
APGE icon

John Overdeck’s Apogee Therapeutics APGE Stock Holding History

John Overdeck’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6M Sell
94,759
-186,627
-66% -$16.8M 0.01% 1340
2026
Q1 		$23.7M Buy
281,386
+176,145
+167% +$12.8M 0.02% 852
2025
Q4 		$7.94M Sell
105,241
-17,134
-14% -$1.08M 0.01% 1288
2025
Q3 		$4.86M Buy
122,375
+6,681
+6% +$255K 0.01% 1484
2025
Q2 		$5.02M Sell
115,694
-136,441
-54% -$5.19M 0.01% 1233
2025
Q1 		$9.42M Sell
252,135
-14,347
-5% -$555K 0.02% 792
2024
Q4 		$12.1M Buy
266,482
+67,174
+34% +$3.43M 0.03% 669
2024
Q3 		$11.7M Sell
199,308
-102,914
-34% -$4.93M 0.03% 689
2024
Q2 		$11.9M Buy
302,222
+212,742
+238% +$10.3M 0.03% 647
2024
Q1 		$5.95M Buy
89,480
+64,441
+257% +$2.81M 0.01% 890
2023
Q4 		$700K Buy
+25,039
New +$502K ﹤0.01% 2285

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

John Overdeck's APGE Position: Q2 2026 in Review

John Overdeck reduced its Apogee Therapeutics (APGE) stake by 66% in Q2 2026, selling an estimated $16.8M and leaving 94,759 shares worth $12.6M. The position accounts for 0.01% of the portfolio, ranked #1340.

John Overdeck first reported a position in APGE in Q4 2023 and has held it in 11 quarters since. The position peaked at $23.7M in Q1 2026. 286 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • John Overdeck held 94,759 shares of Apogee Therapeutics worth $12.6M as of Q2 2026.
  • John Overdeck sold 186,627 Apogee Therapeutics shares in Q2 2026, an estimated $16.8M.
  • Apogee Therapeutics made up 0.01% of John Overdeck's portfolio in Q2 2026, its #1340 holding.
  • John Overdeck first reported a position in Apogee Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • John Overdeck's Apogee Therapeutics position peaked at $23.7M in Q1 2026.
  • 286 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.